HemoShear Hires Industry Business Development Veteran Vincent Aurentz as Chief Business Officer

CHARLOTTESVILLE, Va., Aug. 6, 2013 /PRNewswire/ -- HemoShear, LLC, a leading developer of human-relevant systems for drug discovery and development, today announced that Vincent Aurentz has joined HemoShear as the Company's Chief Business Officer.  Mr. Aurentz is widely respected in the pharmaceutical industry and brings to HemoShear a very strong combination of executive management experience in pharmaceutical R&D, licensing and business development, as well as expertise in building strategic partnerships.  

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO)

Mr. Aurentz has worked for over 24 years in life sciences.  Most recently, he was Executive Vice President of the Customer Solutions Business at Quintiles where he created a new business model to engage their customers.  Previously, he spent almost nine years with Merck KGaA where he served as Executive Vice President, Portfolio Development, for Merck Serono and was a member of the Executive Management Board.   He was responsible for Licensing and Business Development, Global Product leadership for the R&D pipeline, and Portfolio Management.  Prior to his role at Merck Serono, he was Merck KGaA's Global Head of Licensing and Business Development.  Mr. Aurentz is formerly a co-founder and Managing Director of True North Partners, a venture capital and advisory business focused on the healthcare industry. He was also a partner for CSC Healthcare in New York and worked at Andersen Consulting (now known as Accenture).

"I am excited to join HemoShear's talented organization," said Mr. Aurentz.  "I was struck by the quality of the science that HemoShear has developed, its potential to improve the productivity of drug R&D, and their vision for broad partnerships with pharma.  In considering the opportunity to join HemoShear, I spoke with several executives in pharma who shared a consistent message regarding the value of HemoShear's science in understanding human biology and response to new drug candidates at a level that has not existed before."

"Vince is an outstanding addition to HemoShear's executive team.  As we grow, we want to recruit the best people in the industry to drive our business," said James Powers, HemoShear's CEO.  "Vince's expertise will help us unlock the immense value that our enabling science brings to our pharmaceutical partners' drug R&D programs."

About HemoShear, LLC

By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

For information about HemoShear, please visit www.hemoshear.com.

SOURCE HemoShear, LLC